Proanthocyanidins Attenuates Ferroptosis Against Influenza-Induced Acute Lung Injury in Mice by Reducing IFN-γ.

Background: Acute lung injury (ALI) is associated with high morbidity and mortality and is partly driven promoted by ferroptosis. Proanthocyanidins (PAs) is a natural bioactive flavonoid with anti-inflammatory and antioxidant activities. PAs can also significantly protect against acute lung inflammation and ferroptosis in alveolar epithelial cells. However, it is unclear whether PAs can alleviate ALI by reducing ferroptosis. This study aimed to evaluate the protective effects of PAs and the potential mechanisms against Influenza A virus (IAV)induced ALI.Methods: Mice were inoculated nasally with IAV to induce ALI. IAV-induced pulmonary inflammation and ferroptosis was tested by measuring the levels of malondialdehyde (MDA), glutathione (GSH), glutathione peroxidase 4 (GPX4), solute carrier family 7 member 11 (SLC7A11) and acyl-CoA synthetase long-chain family member (ACSL4) in lung tissue. The potential targets that PAs protect against IAV-induced ALI were determined via a systemic pharmacological analysis. The molecular mechanism of PAs in ALI treatment was investigated by assessing the level of inflammation and ferroptosis markers using Western Blot and quantitative real-time PCR.Results: Systemic pharmacological analysis suggested that PAs protect against IAV-induced pneumonia thorough TGF-beta 1 and its relative signaling pathway. PAs effectively alleviated histopathological lung injury, reduced inflammatory cytokines and chemokines secretion, which were increased in IAV-infected mice. Meanwhile, PAs further prevented mouse airway inflammation in ALI, concomitant with the decreased expression TGF-beta 1, smad2/3, p-Smad2, p-Smad3 and ferroptosis mediator IFN-gamma. Furthermore,IFN-gamma promotes cell lipid peroxidation and ferroptosis,PAs significantly reduced MDA and ACSL4 levels and upregulated GSH, GPX4, and SLC7A11.Conclusion: Overall, PAs can attenuate ferroptosis against IAV-induced ALI via the TGF-beta 1/Smad2/3 pathway and is a promising novel therapeutic candidate for ALI.